Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy

2013 ◽  
Vol 13 (11) ◽  
pp. 1201-1220 ◽  
Author(s):  
Nalini Sehgal ◽  
James Colson ◽  
Howard S Smith
2011 ◽  
Vol 15 (9) ◽  
pp. 976-984 ◽  
Author(s):  
Tanja Hechlerl ◽  
Annick Martinl ◽  
Markus Blankenburgl ◽  
Sandra Schroederl ◽  
Joachim Kosfelderl ◽  
...  

2013 ◽  
pp. 89-94
Author(s):  
Van Minh Nguyen

Opioid analgesics have long been considered as among the most effective treatments for pain, but these medications was used without a fully known mechanism of action until finding its receptor. The discovery of opioid receptors in the dorsal horn has opened a new pain treatment. Intrathecal opioids are widely used as useful adjuncts to anesthesia during regional anesthesia, in the treatment of postoperative acute pain and chronic pain treatment. This article summarizes the historical development and examines the current use of intrathecal opioids in the perioperative period. Pharmacology and clinical use were also reviewed in detail, including dosage in different surgeries, side effects and the treatment. Key words: opioid, intrathecal analgesia, regional anesthesia


2005 ◽  
Vol 7 (1) ◽  
pp. 10-15 ◽  
Author(s):  
Anthony H. Guarino ◽  
Martha Cornell

Neuropathic and nociceptive pain are commonly observed in patients with MS. Among the analgesic options available for treating pain in MS, opioids may be too often avoided because of concerns about prescribing restrictions and addictive potential. However, when these fears are misplaced, they deny the patient of a powerful and potentially effective pain reduction option. Proper screening and management can help select appropriate patients for opioid therapy and maintain patients on long-term therapy while monitoring for signs of behaviors such as addiction or diversion. One such method involves entering into a “contract” with the patient with guidelines for renewing prescriptions. Although the literature contains few studies on opioids specific to MS patients, a number of studies support the use of this drug category in patients experiencing neuropathic pain syndromes.


2006 ◽  
Vol 6 ◽  
pp. 472-490 ◽  
Author(s):  
Franca Patrizi ◽  
Steven D. Freedman ◽  
Alvaro Pascual-Leone ◽  
Felipe Fregni

Chronic abdominal visceral pain (CAVP) has a significant clinical impact and represents one of the most frequent and debilitating disorders in the general population. It also leads to a significant economic burden due to workdays lost, reduced productivity, and long-term use of medications with their associated side effects. Despite the availability of several therapeutic options, the management of patients with CAVP is often inadequate, resulting in frustration for both patients and physicians. This may in part be explained by the lack of understanding of the mechanisms underlying chronic pain; in contrast with acute pain in which the pathophysiology is relatively well known and has several satisfactory therapeutic options. Recently, the development of tools for brain investigation, such as functional magnetic resonance imaging, has provided new insights on the pathophysiology of chronic pain. These new data have shown that plastic changes in the central and peripheral nervous system might play an important role in the maintenance of chronic pain. Therefore, approaches aimed at the modulation of the nervous system, rather than the ones interfering with the inflammatory pathways, may be more effective for chronic pain treatment. We propose that noninvasive central nervous system stimulation, with transcranial magnetic stimulation (TMS), might be a novel therapeutic option for CAVP. This paper will present an overview of the pathophysiology and the available therapies for CAVP, focusing on the recent advances in the treatment of this pathology.


2006 ◽  
Vol 2 (6) ◽  
pp. 365 ◽  
Author(s):  
Sulane Do Ouro, MD ◽  
Santiago Esteban, BS ◽  
Una Sibirceva, MD ◽  
Beverly Whittenberg, MD ◽  
Russell Portenoy, MD ◽  
...  

Fentanyl is commonly used systemically or neuraxially for the management of chronic pain. It can be administered intrathecally via implanted pump, but it is generally considered only after trials of intrathecal (IT) morphine and hydromorphone have proven ineffective. Published experience with IT fentanyl is limited, and long-term therapy at relatively high doses has not been described previously. We describe four patients who were treated with IT fentanyl after other analgesic approaches had failed and who gradually underwent dose escalation to levels as high as 20 times those previously reported. Safety and tolerability were maintained during dose titration. Our experience highlights an expanding scope of practice in the use of IT opioids in general and fentanyl specifically and suggests that high-dose fentanyl can be used safely in highly selected patients.


2010 ◽  
Vol 186 (3) ◽  
pp. 1769-1780 ◽  
Author(s):  
Till A. Röhn ◽  
William T. Ralvenius ◽  
Jolly Paul ◽  
Petra Borter ◽  
Marcela Hernandez ◽  
...  

2018 ◽  
Vol 33 (S1) ◽  
pp. 38-45 ◽  
Author(s):  
Evan P. Carey ◽  
Charlotte Nolan ◽  
Robert D. Kerns ◽  
P. Michael Ho ◽  
Joseph W. Frank

2007 ◽  
Author(s):  
Malinda Breda ◽  
Richard Gevirtz ◽  
Melanie A. Greenberg ◽  
James L. Spira

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.


Sign in / Sign up

Export Citation Format

Share Document